Data updated: Mar 10, 2026
GIAPREZA
ANGIOTENSIN II ACETATE
Approved 2017-12-21
1
Indication
--
Phase 3 Trials
1
Priority Reviews
8
Years on Market
Details
- Status
- Discontinued
- First Approved
- 2017-12-21
- Routes
- INTRAVENOUS
- Dosage Forms
- SOLUTION
GIAPREZA Approval History
Loading approval history...
What GIAPREZA Treats
1 FDA approvalsOriginally approved for its first indication in 2017 .
- Other (1)
🔬
Pro Active Pipeline
Ongoing clinical trials by development phase
Loading...
⭐
Pro Key Completed Trials
Completed studies with published results, ranked by significance
Loading...
📊
Trial Timeline
Full development history with FDA approval milestones
Loading...
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
GIAPREZA FDA Label Details
ProGIAPREZA Patents & Exclusivity
Latest Patent: Jan 2037
Patents (135 active)
US11219662
Expires Jan 6, 2037
US9220745
Expires Dec 18, 2034
US10028995
Expires Dec 18, 2034
US10493124
Expires Dec 18, 2034
US11559559
Expires Dec 18, 2034
US11096983
Expires Dec 18, 2034
US9572856
Expires Jul 18, 2031
US9867863
Expires Dec 16, 2029
US10335451
Expires Dec 16, 2029
US10548943
Expires Dec 16, 2029
+ 125 more patents
Source: FDA Orange Book
Want competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.